Alice Melão,  —

Multiple myeloma patients with high levels of the EZH2 enzyme have shorter survival times, regardless of the treatment they receive, a British study reports. The research, “Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control,” appeared in the…

All three relapsed or refractory multiple myeloma patients in the final group of Cellectar Biosciences‘ Phase 1 trial of CLR 131 benefited from treatment, researchers said. Participants had received more than five previous lines of therapy for their cancer. CLR 131 is a phospholipid-drug conjugate (PDC) being developed for the treatment of…

Acupuncture can help ease the nausea and drowsiness that follows an autologous hematopoietic stem cell transplant in  multiple myeloma patients, a new study suggests. These symptoms can be common in patients, as hematopoietic stem cell transplant (HSCT) is preceded by a heavy dose of chemotherapy. Published in the journal Support Care…

The Japanese Ministry of Health, Labor, and Welfare has approved Darzalex (daratumumab) in combination with either Revlimid (lenalidomide) and dexamethasone, or Velcade (bortezomib) and dexamethasone, for the treatment of adults with relapsed or refractory multiple myeloma. “Multiple myeloma is one of the most common forms of blood cancer in…

The U.S. Food and Drug Administration (FDA) recently approved an investigational new drug (IND) application filed by Unum Therapeutics for its ACTR087 T-cell therapy to be used in combination with an anti-tumor antibody for the treatment of relapsed or refractory multiple myeloma. IND status will allow the company to…

New long-term data from the Phase 3 ENDEAVOR trial has shown that relapsed multiple myeloma patients treated with Kyprolis (carfilzomib) plus dexamethasone survive a median of nine months longer than those who received Velcade (bortezomib) and dexamethasone, Amgen announced. The newly-reported 24 percent reduction in the risk of death is even higher…

The U.S. Food and Drug Administration (FDA) has approved Imbruvica (ibrutinib) for the treatment of chronic graft-versus-host-disease (cGVHD), a common complication of stem cell or bone marrow transplant, in adult patients who failed to respond to other treatments. The FDA approval makes Imbruvica the first and only medicine specifically approved for cGVHD…

Sutro Biopharma‘s STRO-001 eliminates or significantly slows the growth of non-Hodgkin lymphoma and multiple myeloma tumors, studies in mice indicate. Sutro expects the results to support its investigational new drug application for STRO-001. The U.S. Federal Drug Administration must approve the application before the company can start clinical trials of the…

Adding Darzalex (daratumumab) to standard care therapies continues to show improved effectiveness in treating relapsed or refractory multiple myeloma, with no related toxicity, according to updated results from the ongoing Phase 3 POLLUX study (NCT02076009) and Phase 3 CASTOR study (NCT02136134). The findings will be presented June 5 at the the…

Israel’s One World Cannabis (OWC) says it’s moving forward to mouse models to test its unique formula of cannabinoid-based therapies targeting cancer cells. This decision followed promising results from preclinical in vitro studies. “After in-depth and extensive review and assessment of the study’s results accumulated so far, OWC’s research committee determined that the…